## 3 Results
### OCT Analysis at the Index Procedure and Follow-Up  
Initial and follow-up OCT measurements are shown in Table 4. The median follow-up time was 12 months (range: 7 to 38 months) and showed no difference in both groups. At the strut analysis, a total of 842 frames (430 in the initial OCT and 412 in the follow-up OCT) and 8552 struts (4328 in the initial OCT and 4224 in the follow-up OCT) were analyzed at initial and follow-up OCT. Regarding initial OCT analysis, there were no significant differences between the two groups in terms of mean lumen area, mean stent area, percentage of malapposed or uncovered struts, and presence of intrastent thrombi. At the follow-up OCT analysis, the percentage of uncovered struts was not significantly different between the Vytorin 10/10 mg and 10/40 mg groups (6.61 \(\pm\) 10.29% vs. 7.57 \(\pm\) 6.45%, \(p\) = 0.297) (Figure 2). Moreover, there was no significant difference in the percentage of malapped struts between the two groups (0.69 \(\pm\) 1.58% vs. 1.55 \(\pm\) 2.72%, \(p\) = 0.489) (Figure 3). Neointimal coverage including mean NIH area and mean percent NIH area were also similar in both groups. Intrastent thrombi were recognized in two individuals in the Vytorin 10/10 mg group and in none in the Vytorin 10/40 mg group at follow-up. \begin{table}
\begin{tabular}{c c c c} \hline \hline
**Laboratory Findings** & **Vytorin 10/10 mg (n = 9)** & **Vytorin 10/40 mg (n = 9)** & \(p\) **Value** \\ \hline Total cholesterol, mg/dL & 184 (160–223) & 174 (145–206) & 0.605 \\ Triglyceride, mg/dL & 103 (75–178) & 112 (78–162) & 0.931 \\ HDL-cholesterol, mg/dL & 33 (30–35) & 40 (35–49) & 0.014 \\ LDL-cholesterol, mg/dL & 123 (88–143) & 122 (85–138) & 0.730 \\ Apolipoprotein B, mg/dL & 89 (82–107) & 97 (0.8–1.1) & 0.340 \\ Apolipoprotein A1, mg/dL & 114 (105–119) & 126 (114–135) & 0.040 \\ Apolipoprotein B/Apo A1 & 0.74 (0.72–0.93) & 0.79 (0.66–0.91) & 0.666 \\ hsCRP, mg/dl & 0.50 (0.43–0.72) & 0.61 (0.14–1.20) & 0.863 \\ Peak CK-MB, ng/ml & 54 (12–154) & 21 (10–189) & 0.387 \\ Peak troponin-I, ng/ml & 12.1 (8.8–47.3) & 9.3 (4.8–40) & 0.546 \\ \hline \hline \end{tabular} Data are expressed as median (IQR); Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein; hsCRP, high-sensitivity C-reactive protein; CK, creatine kinase.  
\end{table} 
Table 2: Laboratory characteristics of patients in both groups. \begin{table}
\begin{tabular}{c c c c} \hline \hline
**Laboratory Finding** & **Vytorin 10/10 mg (n = 9)** & **Vytorin 10/40 mg (n = 9)** & \(p\) **Value** \\ \hline Total cholesterol, mg/dL & 126 (106–151) & 117 (95–133) & 0.387 \\ Triglyceride, mg/dL & 178 (137–414) & 112 (59–137) & 0.008 \\ HDL-cholesterol, mg/dL & 33 (27–37) & 44 (40–47) & 0.004 \\ LDL-cholesterol, mg/dL & 61 (53–70) & 55 (41–75) & 0.489 \\ \(\Delta\) LDL-cholesterol, mg/dL & 55.7 \(\pm\) 25.0 & 61.7 \(\pm\) 22.6 & 0.605 \\ Degree of change of LDL-cholesterol, \% & 46.0 \(\pm\) 10.7 & 50.5 \(\pm\) 13.7 & 0.387 \\ \hline \hline \end{tabular} Data are expressed as median (IQR) or mean \(\pm\) SD; Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein.  
\end{table} 
Table 3: Lipid profiles at follow-up between the two groups. Figure 3: Percentage of malapped struts at follow-up OCT in the Vytorin 10/10 mg and 10/40 mg groups. Abbreviation: OCT, optical coherence tomography. Figure 2: Percentage of uncovered struts at follow-up OCT in the Vytorin 10/10 mg and 10/40 mg groups. Abbreviation: OCT, optical coherence tomography.